After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed
We refresh our ING Benelux Favourites list. We apply a fundamental bottom up approach in which we select stocks which provide the best upside within our Benelux coverage universe and these stocks need clear catalysts. Additions/deletions: We add the following names to the ING Benelux Favourites list: Ageas: Ageas has done multiple deals; its most recent purchase of the 25% stake BNP Paribas had in its Belgian ops, is an accretive deal and we believe makes the Belgian operations ready for a pot...
Moving away from dependence on Asian earnings (now c.30%), while carefully managing its M&A path, we believe AGEAS is well positioned to see an earnings acceleration in the coming years. China upstreams are coming through, while the share price of its Chinese partner CTIH has doubled in 12 months. BNP PARIBAS has increased its stake in the Group (from c.15% to c.23%) at the same time moving out of the Belgian entity AG, and the Belgian government is looking at options to increase its 6.3% stake....
Ageas announces Net Operating Result guidance update Ageas announces Net Operating Result guidance update Today China Taiping Insurance Holding (CTIH) published a pre-announcement on its full year 2025 results related to the announcement made by The Chinese Ministry of Finance and the State Administration of Taxation concerning the corporate income tax treatment in relation to the transition to IFRS17/9. This new regulation requires an update to the deferred taxes reported for the financial years 2023 and 2024. This update will result in a positive one-off impact on the deferred taxe...
Ageas annonce une mise à jour de la guidance du Résultat Opérationnel Net Ageas annonce une mise à jour de la guidance du Résultat Opérationnel Net Aujourd’hui, China Taiping Insurance Holding (CTIH) a publié une préannonce concernant ses résultats pour l’exercice 2025, liée à l’annonce faite par le Ministère chinois des Finances et l’Administration d’État de la Fiscalité concernant le traitement de l’impôt sur les sociétés dans le cadre de la transition vers les normes IFRS17/9. Cette nouvelle réglementation nécessite une mise à jour des impôts différés déclarés pour les exercices 2023 et...
Ageas kondigt bijstelling aan van het verwachte Netto Operationeel Resultaat Ageas kondigt bijstelling aan van het verwachte Netto Operationeel Resultaat Vandaag publiceerde China Taiping Insurance Holding (CTIH) een kennisgeving voorafgaand aan haar resultaten over het volledige jaar 2025 gelinkt aan de aankondiging van het Chinese Ministerie van Financiën en de Staatsadministratie van Belastingen over de behandeling van de vennootschapsbelasting in verband met de overgang naar IFRS17/9. Deze nieuwe regelgeving vereist een bijstelling van de uitgestelde belastingen die werd gerapporteerd...
A director at Argen X SE sold after exercising options/sold 3,625 shares at 695.710EUR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
argenx announced that the FDA has accepted for priority review a sBLA for Vyvgart IV for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG), with a PDUFA target action date of 10 May 2026. The sBLA acceptance and priority review for Vyvgart in seronegative gMG brings argenx a step closer to its aim of having the broadest possible label in this setting. argenx estimates the commercial opportunity for seronegative gMG could add 1...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine recepto...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.